SEPTIN9 and colorectal carcinoma: For example, SEPT9 is approved by the FDA and NMPA as a plasma marker for CRC detection (Potter et al., 2014; Wu et al., 2016), while SFRP2 (Li et al., 2019), KCNQ5 (Jensen et al., 2019), C9orf50 (Jensen et al., 2019), CLIP4 (Jensen et al., 2019) and TFPI2 (Hibi et al., 2011b) were found to be positive in CRC plasma.